Zivadinov part of study that prompts change in FDA labelling for glatiramer acetate (Copaxone)Posted: February 3, 2014
On the basis of results from the GALA study group, which included UB Dept. of Neurology faculty member Robert Zivadinov, MD, PhD, the FDA has approved three-times weekly glatiramer acetate (Copaxone) injections for relapsing-remitting multiple sclerosis. Prior approved dosing required daily injections. The study, which was conducted across 17 countries and involved more than 1400 patients, showed that the three-times weekly regimen is safe and effective, with the advantage of fewer injections. The GALA study was published in the June 2013 issue of Annals of Neurology. Dr. Zivadinov directs the Buffalo Neuroimaging Analysis Center which performed the MRI analysis for the trial.
For the study abstract, click here: http://onlinelibrary.wiley.com/doi/10.1002/ana.23938/abstract